May 15th 2024
Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.
HCV Screening, Care Model Intervention Improve Patient Outcomes
December 15th 2023Patients with HCV who underwent automated routine screening and the addition of a clinical pharmacist to the interdisciplinary patient care model completed treatment and achieved SVR at a greater rate than patients who were not exposed to the study intervention.
From NAFLD to MASLD: 2023 Brings New Liver Disease Nomenclature
December 13th 2023Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.
Study Finds High Hepatitis C Infection Seroprevalence in Pregnant Women
December 8th 2023The seroprevalence of HCV antibody among pregnant women was significantly greater among those with opioid use disorder and HIV infection, as well as in lower-middle-income countries and those with low levels of HDI.
Study Details Ultrasound Prevalence, Clinical Features of NAFLD in Patients with IBD
November 29th 2023The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.
Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study
November 27th 2023Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.
Q&A: The Microbiome and Autoimmune Liver Disease, with Gideon Hirschfield, PhD, MB BChir
November 25th 2023Gideon Hirschfield, PhD, MB BChir, Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the University of Toronto, sat down with HCPLive Hepatology to discuss the role of the microbiome in autoimmune liver disease.
Q&A: Combination OCA-Bezafibrate for PBC, with Cynthia Levy, MD
November 23rd 2023Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.
Empagliflozin Reduces Liver Fat Content Regardless of T2DM, Study Finds
November 15th 2023Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.